Jatt Ii Acquisition CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Talawar Therapeutics and JATT II Acquisition Corp. have entered into a definitive business combination agreement to form a publicly listed biotechnology company focused on developing bispecific antibodies for immunology and inflammatory diseases.